Dennis Dong Hwan Kim

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

S. Voloshin, M. Mauro, N. Chaudhri, 2021 .

A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs.

J. Cortes, M. Mauro, A. Hochhaus, 2021, Blood.

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

S. Mustjoki, B. Druker, J. Cortes, 2019, Leukemia.

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

S. Kapoor, M. Mauro, A. Hochhaus, 2023, Leukemia.

Efficacy and Safety Results from Ascembl, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, Vs Bosutinib in Patients with Chronic Myeloid Leukemia in Chronic Phase after ≥2 Prior Tyrosine Kinase Inhibitors: Update after 48 Weeks

S. Kapoor, J. Cortes, M. Mauro, 2021, Blood.

Tyrosine kinase inhibitors for the frontline management of CML: an overview

Dennis Dong Hwan Kim, 2023, Canadian Hematology Today.